Full-Time

Regulatory Documentation Specialist III

Posted on 6/6/2026

ImmunityBio

ImmunityBio

501-1,000 employees

Develops immunotherapies for cancer and infections

Compensation Overview

$50.48 - $55.53/hr

+ Bonus + Equity Award

Summit, NJ, USA

In Person

Category
Legal & Compliance (1)
Required Skills
Veeva
Requirements
  • Bachelor’s Degree in life sciences or technical discipline with 5+ years of regulatory operations experience in the biotechnology or pharmaceutical industry required; or High school diploma with 9+ years of regulatory operations experience in the biotechnology or pharmaceutical industry required
  • Expert knowledge of Health Authority procedures and guidance regarding document management and electronic submission
  • Expert knowledge of Electronic Document Management Systems
  • Strong knowledge in Veeva Vault especially Veeva RIM
  • Ability to work with firm deadlines and adapt quickly to changing requirements and priorities
  • Strong organizational skills, written and oral communication skills, and attention to detail
Responsibilities
  • Create and maintain electronic project folders for projects
  • Serve as an advisor to internal departments in the preparation and submission of regulatory documentation
  • Generate electronic files for working documents
  • Format documents prepared or received according to stipulated style guides for reports, assessments, regulatory submissions, letters, etc.
  • Format and compile documents according to requirements specified by Regulatory Agencies
  • QC documents (formatting, bookmarking, hyperlinking, document properties) that were prepared by others
  • Create new submissions in submission software following all SOPs and ensuring all checklists are completed
  • Publish documents (internal bookmarks and hyperlinks), insert into XML backbone (docuBridge), and complete external hyperlinks to other documents and datasets on the XML backbone
  • Submit documents to Health Authorities
  • Ensure that all working files, forms, signout sheets, and archives are organized and maintained in accordance with SOPs and Health Authority requirements
  • Prepare templates and document shells for inclusion of text and data
  • Assist in training Regulatory Documentation Specialists ensuring that all SOPs are followed, and all questions are answered; Continue to provide support and assist in questions after the training is completed
  • Collaborate with other Regulatory Documentation Specialists regarding upgrades to existing software programs, new software programs, or removing software programs that are no longer needed
  • Performs ad-hoc and cross-functional duties and/or projects as assigned to support business needs and provide developmental opportunities

ImmunityBio develops immunotherapies to treat cancer and infectious diseases. It uses natural killer (NK) cell–based therapies and viral vector vaccines to boost the immune system and enable immune cells to attack tumors or infections. The company generates revenue from product sales and licensing agreements, and it focuses on therapies for hard-to-treat cancers and infectious diseases through research, development, and commercialization. Its goal is to outsmart diseases by leveraging the body's natural defenses to give patients more treatment options.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Culver City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Papillary NMIBC sBLA has a January 6, 2027 FDA decision date.
  • ANKTIVA delivered 2025 revenue of $113.3 million, up 668% year over year.
  • Tokyo-172 BCG rights and expanding international approvals could widen the bladder franchise.

What critics are saying

  • ANKTIVA still drives most revenue, so any label or reimbursement setback hurts hard.
  • Papillary approval depends on extrapolated single-arm data, creating clear FDA rejection risk.
  • BCG shortages and manufacturing scaling remain operational bottlenecks for bladder cancer growth.

What makes ImmunityBio unique

  • Vertically integrated commercial-stage biotech built around ANKTIVA and cell therapy platforms.
  • ANKTIVA is FDA-approved for BCG-unresponsive NMIBC CIS and activates NK, T, memory T cells.
  • Management is pursuing cancer vaccines, infectious-disease immunotherapies, and lower-toxicity alternatives to chemotherapy.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at ImmunityBio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Discounts

Wellness Program

Mental Health Support

Performance Bonus

Pet Insurance

529 Education Savings Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
AbstractCore
May 20th, 2026
ANKTIVA plus BCG outperforms approved NMIBC therapies in AUA 2026 analyses.

ANKTIVA plus BCG outperforms approved NMIBC therapies in AUA 2026 analyses. ImmunityBio presented new comparative data at AUA 2026 showing ANKTIVA(R)(nogapendekin alfa inbakicept-pmln) plus BCG delivers longer-lasting responses and fewer adverse events than FDA-approved therapies in BCG-unresponsive NMIBC. ImmunityBio reported new comparative effectiveness data at the 2026 American Urological Association Annual Meeting showing that ANKTIVA(R)(nogapendekin alfa inbakicept-pmln; NAI) combined with Bacillus Calmette-Guérin (BCG) delivered longer-lasting responses and favorable safety outcomes in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. The analyses compared NAI plus BCG against two FDA-approved therapies: nadofaragene firadenovec-vncg and TAR-200. Both studies used matching-adjusted indirect comparison (MAIC) methods because no head-to-head randomized trials currently exist. ANKTIVA is a first-in-class IL-15 agonist fusion complex that activates natural killer (NK) cells and CD8+ T cells to strengthen anti-tumor immune activity and sustain immune memory. The therapy targets a major unmet need in BCG-unresponsive NMIBC, where patients often face radical cystectomy after limited bladder-sparing treatment options fail. In the first analysis, investigators compared individual patient data from the QUILT-3.032 study with aggregate data from the nadofaragene firadenovec trial. After statistical adjustment, NAI plus BCG achieved an anytime complete response rate of 69.7% compared with 53.4% for nadofaragene. Median duration of complete response reached 22.1 months versus 9.7 months, while cystectomy-free survival improved with a hazard ratio of 0.40. Overall survival did not differ significantly between groups. A second MAIC analysis compared NAI plus BCG with TAR-200 using data from the SunRISe-1 study. At 12 months, complete response rates numerically favored NAI plus BCG, although the difference was not statistically significant. However, treatment-related adverse events occurred substantially less often with NAI plus BCG, with investigators reporting a 68% reduction in adverse event odds versus TAR-200. Investigators noted that both analyses carry the limitations inherent to unanchored indirect comparisons, including incomplete alignment of baseline tumor characteristics across trials. Still, sensitivity analyses produced consistent findings across efficacy and safety endpoints. ImmunityBio said the findings support ANKTIVA plus BCG as a potential immunologic backbone for bladder-preserving treatment strategies while the company continues development efforts tied to recombinant BCG and alternative BCG supply sources amid ongoing U.S. shortages. About the Writer Dr.Preethi Putti, PharmD (LinkedIn) is a pharmaceutical researcher with experience in healthcare and pharmaceutical market research and competitive intelligence. She specializes in analyzing drug pipelines, clinical data, and industry trends and translating complex scientific data into clear and structured medical content. Strong foundation in clinical research, data interpretation, and evidence-based healthcare analysis. Committed to advancing a global career in clinical research and healthcare innovation.

Yahoo Finance
Apr 14th, 2026
ImmunityBio reports $44.2M Q1 revenue from ANKTIVA expansion across 33 countries

ImmunityBio has reported preliminary Q1 2026 net product revenue of approximately $44.2 million, driven by uptake of its drug ANKTIVA and broader approvals. The company's shares currently trade at $7.60, having surged 276% year-to-date, though they fell 9.42% over the past month. Despite recent momentum, the stock has posted a 54% loss over five years, reflecting uneven performance tied to ANKTIVA revenue progress and ongoing regulatory and legal challenges. The most popular analyst narrative values ImmunityBio at $13.50 per share, suggesting 43.7% upside. This valuation assumes aggressive growth from ANKTIVA's expansion into 33 countries, including the US, EU and Saudi Arabia, alongside commercial partnerships. However, this outlook depends on regulatory support, expanded indications beyond bladder cancer, and strong market uptake.

My Malone Telegram
Apr 12th, 2026
IBRX investors have opportunity to lead ImmunityBio, Inc. securities fraud lawsuit first filed by the Rosen Law Firm.

IBRX investors have opportunity to lead ImmunityBio, Inc. securities fraud lawsuit first filed by the Rosen Law Firm. * 2 hrs ago PR Newswire NEW YORK, April 11, 2026 NEW YORK, April 11, 2026 /PRNewswire/ - Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A.

Business Insider
Apr 10th, 2026
Berger Montague PC investigating claims on behalf of ImmunityBio, Inc. (IBRX) investors after class action filing.

Berger Montague PC investigating claims on behalf of ImmunityBio, Inc. (IBRX) investors after class action filing. Apr. 10, 2026, 08:41 AM Philadelphia, Pennsylvania-(Newsfile Corp. - April 10, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026 (the "Class Period"). Headquartered in San Diego, Calif., ImmunityBio is a clinical-stage biopharmaceutical company developing cancer immunotherapies and vaccines, including the Anktiva platform. According to the Complaint, throughout the Class Period, defendants made materially false and misleading statements about the capabilities of Anktiva. Specifically, the Complaint alleges that during an appearance on a podcast, Chief Scientific and Medical Officer Patrick Soon-Shiong claimed that Anktiva can cure and even prevent all cancer. When the true details entered the market, ImmunityBio's stock declined by $1.98 per share, more than 21%, to close at $7.42 per share on March 24, 2026. If you are an ImmunityBio investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger Montague Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. Andrew Abramowitz Berger Montague (215) 875-3015 [email protected] Caitlin Adorni Berger Montague (267) 764-4865 [email protected] Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Sponsored Financial Content

The Associated Press
Apr 9th, 2026
ImmunityBio Q1 revenue surges 168% to $44M with $381M cash on hand

ImmunityBio has reported preliminary net product revenue of $44.2 million for the quarter ending 31 March 2026, representing a 168% increase over the same period in 2025 and a 15% sequential increase from the previous quarter. The commercial-stage biotechnology company's product ANKTIVA has driven consistent quarterly revenue growth since its commercial launch. The company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities. ANKTIVA is now approved or authorised across five regulatory jurisdictions representing approximately 34 countries. ImmunityBio's pivotal BCG-naïve CIS trial is fully enrolled, with a supplemental biologics licence application submission on track for 2026. The company reported full-year 2025 net product revenue of $113 million, a 700% increase over 2024.